Kristen Beebe

Kristen Beebe

Auto-generated profile, based on publicly available information

Kristen Beebe

Blood and Marrow Transplantation, Mayo Clinic Arizona and Phoenix Children's Hospital, Phoenix, Arizona

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2024 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
SRSeth J. Rotz
Seth J. Rotz
NBNeel S. Bhatt
Neel S. Bhatt
BHBetty K. Hamilton
Betty K. Hamilton
CDChristine Duncan
Christine Duncan
MAMahmoud Aljurf
Mahmoud Aljurf
RPRachel Phelan
Rachel Phelan
As hematopoietic cell transplantation (HCT) and cellular therapy expand to new indications and international access improves, the number of HCTs performed annually continues to rise. Parallel improvements in HCT techniques and supportive care entails more patients surviving long term, creating further emphasis on survivorship needs. Survivors are at risk for developing late complications secondary to pretransplantation, peritransplantation, and post-transplantation exposures and other underlying risk factors. Guidelines for screening and preventive practices for HCT survivors were originally published in 2006 and then updated in 2012. An international group of experts was convened to review the contemporary literature and update the recommendations while considering the changing practices of HCT and cellular therapy. This review provides updated pediatric and adult survivorship guidelines for HCT and cellular therapy. The contributory role of chronic graft-versus-host disease (cGVHD) to the development of late effects is discussed, but cGVHD management is not covered in detail. These guidelines emphasize the special needs of patients with distinct underlying HCT indications or comorbidities (eg, hemoglobinopathies, older adults) but do not replace more detailed group-, disease-, or condition-specific guidelines. Although these recommendations should be applicable to the vast majority of HCT recipients, resource constraints may limit their implementation in some settings.

14 December 2024 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
RHRhea Hans
Rhea Hans
CSCharlotte Schwalbach
Charlotte Schwalbach
RARoberta H. Adams
Roberta H. Adams
HMHolly Miller
Holly Miller
DSDana Salzberg
Dana Salzberg
ANAlexander Ngwube
Alexander Ngwube
Several adult studies show mixed reports in clinical outcomes between cryopreserved and fresh stem cell products, with majority reporting no significant differences and others report that there are differences in outcomes. There is limited literature reporting its impact on outcomes in pediatric hematopoietic cell transplantation (HSCT). To compare clinical outcomes between fresh vs cryopreserved stem cell treatment in pediatric HSCT. A retrospective chart review was conducted on allogenic HSCT at Phoenix Children's Hospital between January 1, 2016, and March 31, 2023. The study included 181 patients, with 105 receiving fresh stem cell products and 76 receiving cryopreserved products. Clinical outcomes including, neutrophil and platelet recovery, graft versus host disease, immune reconstitution and survival outcome were compared. Study subjects had median follow-up of 997 (range 12-2642) days. 92 patients were treated for a malignant disease (leukemia/lymphoma) and 89 were treated for a non-malignant disease (hemoglobinopathies, immunodeficiency/immune dysregulation, and bone marrow failure). 124 stem cell products were from bone marrow and 57 were from peripheral blood. Comparisons between fresh vs cryopreserved treatments found no significant difference in days to neutrophil engraftment (p=0.47) or platelet engraftment (p=0.94). No difference in the incidence of acute graft versus host disease or chronic graft versus host disease (p = 0.70) between both groups. Immune reconstitution at 365 days post-transplant did not vary significantly between treatment groups for CD4+ T cells, CD8+ T cells, CD19+ B cells, and CD56/16+ NK cells. Overall survival at 2 years was similar in the fresh vs cryopreserved (86.7% vs 84.2%; p = 0.64). These observations suggest that cryopreserved stem cell product is a reasonable alternative with comparable efficacy and potentially offering logistical advantages. Further research with larger pediatric cohorts is recommended to confirm non-inferiority of cryopreserved treatments in pediatric HSCT.

22 January 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
BSBlachy J Dávila Saldaña
Blachy J Dávila Saldaña
KSKirk R Schultz
Kirk R Schultz
ARArchana Ramgopal
Archana Ramgopal
JBJulie R. Boiko
Julie R. Boiko
KBKristen Beebe
Kristen Beebe
KWKirsten M Williams
Kirsten M Williams
While highly morbid forms of chronic graft versus host disease (cGVHD) and severe late effects of allogeneic hematopoietic cell transplantation (HCT) can impact children and adults alike, unique considerations arise in pediatric cases regarding diagnosis, monitoring, treatment, and likelihood of resolution. As children can present with atypical features of cGVHD and with more significant disease due to inability to communicate symptoms, they may be at increased risk for highly morbid forms of cGVHD and incur greater subsequent late effects, which may be more pronounced in those with underlying chromosomal breakage syndromes, with higher prevalence in pediatric HCT recipients. The long-term effects of cGVHD and its therapies include impaired immune reconstitution, leading to increased risks of infection and secondary malignant neoplasms. However, children also have the greatest potential for full immune reconstitution, due to thymus recovery that could impact the timing of vaccination with respect to tolerance and restoration of optimal immunity. Developing strategies to mitigate the late effects incurred with, and as a result of, cGVHD is of critical importance. The working group recommends surveillance strategies for late effects in patients with cGVHD, increased utilization of emerging diagnostic tools, integration of monitoring for cGVHD treatment response, and development of new treatments and specifies aims of future research endeavors.